NYX-2925 Continues to Significantly Reduce Pain Severity Marker in Phase 2 Trial, Top Line Data Shows
News
Aptinyx’s NYX-2925 treatment candidate continues to significantly reduce the levels of a brain biomarker associated with pain severity, called glutamine (Glx), in people with fibromyalgia, top line results of a ... Read more